| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
OGT2378 manufacturers
- Sinbaglustat
-
- $66.00
-
2026-07-15
- CAS:441061-33-2
- Purity: 99.97%
- Supply Ability: 10g
|
| | OGT2378 Basic information |
| Product Name: | OGT2378 | | Synonyms: | OGT2378;ACT-519276;Sinbaglustat;3,4,5-Piperidinetriol, 2-(hydroxymethyl)-1-pentyl-, (2S,3R,4R,5S)-;Sinbaglustat, 10 mM in DMSO | | CAS: | 441061-33-2 | | MF: | C11H23NO4 | | MW: | 233.3 | | EINECS: | | | Product Categories: | | | Mol File: | 441061-33-2.mol |  |
| | OGT2378 Chemical Properties |
| Boiling point | 405.5±45.0 °C(Predicted) | | density | 1.201±0.06 g/cm3(Predicted) | | pka | 13.71±0.70(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | OGT2378 Usage And Synthesis |
| Uses | Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions[1][2]. | | in vivo | Sinbaglustat (OGT2378; administered p.o., in the powdered chow, at a dose of 2500 mg/kg/day, corresponding to 35-40 mg of Sinbaglustat per mouse per day) is highly effective in impeding melanoma tumor growthin vivo. The effectiveness of p.o. Sinbaglustat in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising approach to inhibit tumor progression[1]. | Animal Model: | Female syngeneic C57BL/6 mice, 6-8 weeks old bearing MEB4 melanoma tumor[1] | | Dosage: | 35-40 mg per mouse per day | | Administration: | Administered p.o., in the powdered chow, at a dose of 2500 mg/kg/day | | Result: | Inhibited MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model.
|
| | References | [1] Michael Weiss,et al. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res.2003 Jul 1;63(13):3654-8. PMID:12839955
[2] Martine Gehin,et al. Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders. Clin Transl Sci.2021 Mar;14(2):558-567. DOI:10.1111/cts.12911 |
| | OGT2378 Preparation Products And Raw materials |
|